Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year overall survival (OS) data from CheckMate -017 and CheckMate -057, two pivotal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Bristol-Myers Squibb (BMY) Reports Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) in Phase 3 CheckMate -238 StudySeptember 11, 2017 6:21 AM Bristol-Myers Squibb (BMY) Reports Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival in Phase 3 CheckMate -214 TrialSeptember 11, 2017 6:16 AM Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung CancerSeptember 8, 2017 5:30 AM Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at Goldman Sachs, Positively Revises EPS EstimatesSeptember 7, 2017 9:53 AM Wall St. ends flat as media stocks slump, healthcare gainsSeptember 7, 2017 7:39 AM Bristol-Myers Squibb (BMY) Reports CheckMate-214 Study Evaluating Opdivo in Combination with Yervoy Meets Co-Primary Endpoint, Demonstrating Superior Overall Survival Compared to SunitinibSeptember 7, 2017 7:02 AM Bristol-Myers Squibb (BMY) Offers Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma on Partial Clinical HoldSeptember 6, 2017 5:26 PM